AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
- Details
- Category: AstraZeneca
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
The trial design is based upon strong scientific evidence supporting the role of the Bruton's tyrosine kinase (BTK) pathway in
Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries
- Details
- Category: Sanofi
Sanofi has committed to donating 100 million doses of hydroxychloroquine to 50 countries around the world, and has begun to progressively deliver the medicine to authorities that have requested it.
In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations.
Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development
- Details
- Category: Pfizer
BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), and Pfizer Inc. (NYSE: PFE) disclosed additional details of their collaboration to advance candidates from BioNTech's mRNA vaccine program, previously announced on March 17, 2020.
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
- Details
- Category: Novartis
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.
Johnson & Johnson announces a lead vaccine candidate for COVID-19
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) (the Company) announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA);
Amgen and Adaptive Biotechnologies announce strategic partnership to develop a therapeutic to prevent or treat COVID-19
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.
More Pharma News ...
- First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
- Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
- Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
- Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
- Roche response to COVID-19 pandemic
- AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
- Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response